Skip to main navigation Skip to search Skip to main content

Defining Value of Cancer Therapeutics-A Health System Perspective

  • Christine Leopold*
  • , Jeffrey M Peppercorn
  • , S Yousuf Zafar
  • , Anita K Wagner
  • *Corresponding author for this work
  • Harvard Medical School and Harvard Pilgrim Health Care Institute
  • Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Harvard Medical School and Harvard Pilgrim Health Care Institute

Research output: Contribution to journal › Review article › peer-review

Abstract

Because of the rising costs of cancer care and ongoing challenges in ensuring access to quality care, there is an increasing need to prioritize spending and define the benefits of therapy in proportion to costs. The term "value" has gained favor as means to define the relative utility of a medical intervention in terms of benefits, risks, and financial costs, which in turn can help clinicians, patients, and policy makers prioritize "high-value" care. While numerous value concepts have been proposed, a comprehensive discussion of value initiatives along the care continuum is missing. In this Commentary, we propose a health system taxonomy of value initiatives in cancer care to discuss what the field needs to progress.

Original languageEnglish
Pages (from-to)699-703
Number of pages5
JournalJournal of the National Cancer Institute
Volume110
Issue number7
DOIs
Publication statusPublished - 1 Jul 2018
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cost-Benefit Analysis
  • Health Services Accessibility/economics
  • Humans
  • Medical Oncology/economics
  • Neoplasms/economics
  • Quality of Health Care/economics

Fingerprint

Dive into the research topics of 'Defining Value of Cancer Therapeutics-A Health System Perspective'. Together they form a unique fingerprint.

Cite this